SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer. Clinical Cancer Research 2009, 15: 4674-4679. PMID: 19584151, PMCID: PMC2819274, DOI: 10.1158/1078-0432.ccr-09-0227.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overFemaleGene DeletionHumansKaplan-Meier EstimateMaleMiddle AgedMutationPancreatic NeoplasmsPrognosisProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaSmad4 ProteinTumor Suppressor Protein p53ConceptsPoor prognosisPancreatic cancerLymph node statusShorter overall survivalSMAD4 gene mutationUnderwent pancreaticoduodenectomyOverall survivalMargin statusNode statusTumor sizePatient outcomesPatientsAdenocarcinomaPancreasCancerPrognosisGene mutationsSMAD4 inactivationGene inactivationSomatic mutationsHomozygous deletionMonthsSurvival